https://jbmtct.com.br/seer/index.php/jbmtct/issue/feed JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY 2024-09-02T16:05:26+00:00 Fernando Barroso Duarte journalbmtct@sbtmo.org.br Open Journal Systems <p>The JBMTCT is an official electronic scientific publication of the Brazilian Society of Bone Marrow Transplantation (SBTMO), created in 2020, edited every three months and in compliance with a defined editorial policy.</p> <p>Publishes letter to the editor, unpublished articles, review articles, short communication, opinion articles, case reports, conduct protocols and research articles in progress / completed with the aim of spreading knowledge and innovative research in medicine fields, bone marrow transplantation, cell therapy and related sciences.</p> <p>Target audience: this journal is aimed to researchers, teachers, professionals and students with an interest in the medicine field (bone marrow transplantation and cell therapy) and related sciences.<br /><br />Periodicity of the jornal:<br />Quarterly</p> https://jbmtct.com.br/seer/index.php/jbmtct/article/view/237 Commentary article on AI and EI 2024-07-22T13:41:43+00:00 Hans-Jochem Kolb h-j-kolb@web.de 2024-07-24T00:00:00+00:00 Copyright (c) 2024 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://jbmtct.com.br/seer/index.php/jbmtct/article/view/244 HEMATOPOIETIC CELL TRANSPLANTATION (HCT) FOR ALL: A report from the 2024 Congress of the Brazilian Bone Marrow Transplantation and Cellular Therapy Society (SBTMO) 2024-09-02T16:05:26+00:00 Fernando Barroso Duarte nutriquimo@uol.com.br Karine Sampaio Nunes Barroso karinesampaionb@gmail.com Luiz Guilherme Darrigo Juniro darrigo.jr@gmail.com Carmem Maria Sales Bonfim carmembonfim@gmail.com <p>This article analyzes current data, and the main challenges faced in Hematopoietic cell Transplantation (HCT) in Brazil, as presented at the SBTMO 2024 meeting, with the aim of guiding future actions. Topics discussed included the waiting list for HCT transplants, access to beds for adults and pediatric patients, and the need for a more efficient distribution of resources across the country. Among the identified needs were the creation of a program to expand access to transplants through the Brazilian Unified Health System (SUS), the importance of health registries for data-driven decisions, and the development of the <em>"Mais Saúde Amazônia"</em> project to expand transplant centers in the Amazon region. Additionally, the provision of financial incentives for transplant centers, the implementation of mentorship programs to increase access to HCT, and the formation of a cooperative network between SBTMO (Brazilian Society of Bone Marrow Transplantation and Cellular Therapy), ABHH (Brazilian Association of Hematology, Hemotherapy, and Cellular Therapy), ANVISA (Brazilian Health Regulatory Agency), ABRALE (Brazilian Association of Lymphoma and Leukemia), and INCA (Brazilian National Cancer Institute) to improve the integration of HCT services were discussed</p> 2024-09-25T00:00:00+00:00 Copyright (c) 2024 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY https://jbmtct.com.br/seer/index.php/jbmtct/article/view/235 EMERGING ACTIVITY OF CELLULAR IMMUNOTHERAPY FOR TREATMENT OF CANCER IN BRAZIL 2024-07-05T11:40:03+00:00 Cinthya Corrêa da Silva cinthya.silva@einstein.br Anderson João Simione ajsimione@hotmail.com Paula Moreira da Silva Sabaini pauladc@gmail.com Antonio Vaz Macedo antoniovmac@gmail.com Heliz Regina Alves das Neves heliz.neves@hc.ufpr.br Monique Ammi mammi@NMDP.ORG Flavia Ferreira da Costa flaviafdacosta@gmail.com Valeria Viana valeriavianna.ufrj@gamil.com Adriana Mendes de Quadros Cavilha adriana.cavilha@hc.ufpr.br Rosana Rocha Concilio rosana.concilio@bp.org.br Phillip Scheinberg scheinbp@bp.org.br Nelson Hamerschlak hamer@einstein.br Marco Aurelio Salvino marcohemato@hotmail.com Adriana Seber adrianaseber@gmail.com Yana Augusta Sarkis Novis yananovis@yahoo.com Vanderson Geraldo Rocha vanderson.rocha@hc.fm.usp.br Joaquim Gasparini dos Santos joaquimgasparini@gmail.com Lucia Mariano da Rocha Silla dralucia.silla@gmail.com Ricardo Chiattone ricardo.chiattone@gmail.com Andreza Alice Feitosa Ribeiro andreza.ribeiro@einstein.br Vaneuza Araújo Moreira Funke vfunke@gmail.com Leonardo Javier Arcuri leonardo.arcuri@einstein.br Lucila Nassif kerbauy lucila.kerbauy@einstein.br Jayr Schmidt Filho jayrsf@gmail.com Carmem Maria Sales Bonfim carmem.bonfim@gmail.com Simone Ojima Ferreira simone.ojima@gmail.com Marcelo Pasquini mpasquini@mcw.edu Fernando Barroso Duarte nutriquimio@uol.com.br <p>Chimeric antigen receptor T-cells (CAR T cells) are genetically modified cellular immunotherapies approved for standard of care treatment of patients with lymphoma and leukemia worldwide. Here we report the initial activity in Brazilian centers through the collaboration between the Brazilian Cellular Therapy and Bone Marrow Transplant Society (SBTMO) and Center for International Blood and Marrow Transplant Research (CIBMTR).&nbsp; A total of 38 patients who received CAR T cells between 2020 and 2023. The median age was 47 years (range 4-77). Indications include Non-Hodgkin Lymphoma (NHL; 26 cases; 68%), Acute Lymphoblastic Leukemia (ALL; 9 cases; 24%), and Multiple Myeloma (MM; 3 cases; 8%). &nbsp;84% (75% - 24 NHL cases and 25% - 8 ALL cases) were commercial.&nbsp; This report demonstrates the initial implementation of CAR T cells in Brazil among centers that report to the SBTMO/CIBMTR. This infrastructure will assist in further capturing the activity, assessing the outcomes, and complying with regulatory requirements.&nbsp;</p> 2024-07-24T00:00:00+00:00 Copyright (c) 2024 JOURNAL OF BONE MARROW TRANSPLANTATION AND CELLULAR THERAPY